Catalyst Wire Dossier Catalyst Wire Dossier

Cinrebafusp alfa

cinrebafusp alfa · Pieris Pharmaceuticals, Inc.
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Cinrebafusp alfa, covering 2022-09-08 to 2022-09-08. Get the full timeline:

Most recent: Clinical Trial Update: Cinrebafusp Alfa in Combination With Ramucirumab and Paclitaxel in HER2-High Gastric or GEJ Adenocarcinoma and in Combination With Tucatinib in HER2-Low Gastric or GEJ Andenocarinoma [Phase 2]

See pricing